ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Hitachi expands in regenerative medicine with Apceth acquisition

by Rick Mullin
February 8, 2019 | APPEARED IN VOLUME 97, ISSUE 6

 

Aiming to expand its presence in Europe as well as its business in regenerative medicines, Hitachi Chemical will acquire Apceth Biopharma, a German contract manufacturer, for about $85 million. The deal follows Hitachi’s purchase of PCT, a US regenerative medicines contractor, in 2017 and the opening of a contract development and manufacturing facility in Yokohama, Japan, last April. Apceth specializes in producing cancer immunotherapy cells, induced pluripotent stem cells, and mesenchymal stem cells.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment